Claims
- 1. A method of attenuating the formation of a bruise in traumatized tissue of a patient, the method comprising applying a composition comprising a hydrophilic foam substrate and a polymeric hydrophilic agent capable of absorbing water to a portion of the surface of the skin of the patient in an amount and at a location sufficient to attenuate the formation of a bruise in the traumatized tissue.
- 2. The method of claim 1, wherein the tissue is traumatized as a result of a surgical procedure.
- 3. The method of claim 1, wherein the tissue is traumatized as a result of an injury.
- 4. The method of claim 1, wherein the tissue is muscle, bone, ligament, or skin.
- 5. The method of claim 1, wherein the hydrophilic foam comprises the in situ reaction product of a isocyanate-capped polyether prepolymer.
- 6. The method of claim 1, wherein the prepolymer is selected from the group consisting of isocyanate-capped polyether polyols having an isocyanate equivalent weight of from about 0.5 meq/g to about 3.0 meq/g and mixtures thereof.
- 7. The method of claim 1, wherein the hydrophilic agent is selected from the group consisting of starch grafted copolymers of acrylate salts, starch grafted copolymers of acrylamide salts, polyacrylate salts, and mixtures thereof.
- 8. The method of claim 1, wherein the hydrophilic agent comprises an additive selected from the group consisting of methylcellulose, guar gum, pectin, karaya gum, chitosan, agar, acacia powder, carrageenan, gelatin, and mixtures thereof.
- 9. The method of claim 1, wherein the composition further comprises an alcohol selected from the group consisting of water soluble monols, diols and polyhydric alcohols.
- 10. The method of claim 1, wherein the composition further comprises an alcohol selected from the group consisting of ethanol, isopropyl alcohol, propylene glycol, polyethylene glycol, polypropylene glycol, glycerin, 1,2,4-butanetriol, trimethylolpropane, sorbitol, pentaerythritol, and mixtures thereof.
- 11. The method of claim 1, wherein the composition further comprises a therapeutic agent.
- 12. The method of claim 11, wherein the therapeutic agent is selected from the group consisting of soluble collagen, hydrolyzed collagen, collagen amino acids salt free, hydrolyzed animal protein and hyaluronic acid, an ointment including methyl salicylate and menthol and hydrocortisone acetate, polymers with medicinal properties, and trans-retinoic acid.
- 13. The method of claim 1, wherein the hydrophilic agent is incorporated into the foam substrate.
- 14. The method of claim 14, which further comprises a wetting agent.
- 15. The method of claim 14, wherein the wetting agent is a non-ionic surfactant selected from the group consisting of block copolymers of ethylene oxide and propylene oxide, ethoxylated sorbitan fatty acid esters, glycerol esters, polyglycerol esters, silicone fluids and mixtures thereof.
- 16. The method of claim 1, wherein the patient is a human.
- 17. A method of attenuating swelling or inflammation within the tissue of a patient, the method comprising applying a composition comprising a hydrophilic foam substrate and a polymeric hydrophilic agent capable of absorbing water to the surface of the skin of the patient in an amount and at a location sufficient to attenuate swelling or inflammation within the tissue.
- 18. The method of claim 17, which attenuates neurogenic inflammation with the tissue.
- 19. The method of claim 18, wherein the neurogenic inflammation is a response to a noxious stimulus.
- 20. The method of claim 18, wherein the neurogenic inflammation is a symptom of a disease.
- 21. The method of claim 20, wherein the disease is selected from the group of diseases consisting of acne, morphea, and eczema,
- 22. The method of claim 17, wherein the tissue is muscle, bone, ligament, or skin.
- 23. The method of claim 1, wherein the hydrophilic foam comprises the in situ reaction product of a isocyanate-capped polyether prepolymer.
- 24. The method of claim 17, wherein the prepolymer is selected from the group consisting of isocyanate-capped polyether polyols having an isocyanate equivalent weight of from about 0.5 meq/g to about 3.0 meq/g and mixtures thereof.
- 25. The method of claim 17, wherein the hydrophilic agent is selected from the group consisting of starch grafted copolymers of acrylate salts, starch grafted copolymers of acrylamide salts, polyacrylate salts, and mixtures thereof.
- 26. The method of claim 17, wherein the hydrophilic agent comprises an additive selected from the group consisting of methylcellulose, guar gum, pectin, karaya gum, chitosan, agar, acacia powder, carrageenan, gelatin, and mixtures thereof.
- 27. The method of claim 1, wherein the composition further comprises an alcohol selected from the group consisting of water soluble monols, diols and polyhydric alcohols.
- 28. The method of claim 17, wherein the composition further comprises an alcohol selected from the group consisting of ethanol, isopropyl alcohol, propylene glycol, polyethylene glycol, polypropylene glycol, glycerin, 1,2,4-butanetriol, trimethylolpropane, sorbitol, pentaerythritol, and mixtures thereof.
- 29. The method of claim 1, wherein the composition further comprises a therapeutic agent.
- 30. The method of claim 29, wherein the therapeutic agent is selected from the group consisting of soluble collagen, hydrolyzed collagen, collagen amino acids salt free, hydrolyzed animal protein and hyaluronic acid, an ointment including methyl salicylate and menthol and hydrocortisone acetate, polymers with medicinal properties, and trans-retinoic acid.
- 31. The method of claim 17, wherein the hydrophilic agent is incorporated into the foam substrate.
- 32. The method of claim 17, which further comprises a wetting agent.
- 33. The method of claim 32, wherein the wetting agent is a non-ionic surfactant selected from the group consisting of block copolymers of ethylene oxide and propylene oxide, ethoxylated sorbitan fatty acid esters, glycerol esters, polyglycerol esters, silicone fluids and mixtures thereof.
- 34. The method of claim 17, wherein the patient is a human.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This is a divisional application of copending U.S. patent application Ser. No. 09/326,836, filed Jun. 7, 1999, which claims priority to United States Provisional Patent Application No. 60/088,424, filed Jun. 8, 1998.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60088424 |
Jun 1998 |
US |
Divisions (1)
|
Number |
Date |
Country |
Parent |
09326836 |
Jun 1999 |
US |
Child |
09789275 |
Feb 2001 |
US |